The Chinese market for X-ray equipment will grow 50 percent from 2012 levels to reach more than $1.5 billion by 2017, according to a new report from HIS.

To help reduce the burden of cardiovascular disease, the nation's leading killer, New York-Presbyterian Hospital and Weill Cornell Medical College have created the Dalio Institute of Cardiovascular Imaging. Raymond T. Dalio, a life trustee of New York-Presbyterian Hospital, has made a gift of $20 million through his Dalio Foundation in support of the institute.

Picture Archiving and Communication System (PACS) vendor DR Systems will exhibit new capabilities designed to increase the quality and efficiency of patient services at the Radiological Society of North American Annual Meeting (RSNA) 2013.

The Eurozone economic slowdown has made it difficult for hospitals, particularly in Southern Europe, to procure new imaging modalities. With streamlined budgets and escalating number of medical procedures, the need to spend less on technologies while gaining the maximum benefit from them has sustained demand for high-quality refurbished imaging equipment.


Radcal Corp. will launch its new models of diagnostic X-ray meters and sensors, Accu-Gold+ and Rapid-Gold+ with improved stacked sensor multisensors including a dual rad/fluoro and mammo all-in-one multisensor, at the Radiological Society of North American Annual Meeting (RSNA 2013).

Indianapolis-based Modular Devices Inc. reported it expanded its fleet of interim labs to include more computed tomography (CT) scanner options.  The turnkey labs are available to medical centers around the country for short and long-term leases.  

A University of Colorado Cancer Center study, published in the journal Physics in Medicine and Biology, shows that endorectal balloons commonly used during precise radiation treatment for prostate cancer can deform the prostate in a way that could make radiation miss its mark.

Lantheus Medical Imaging, Inc., a developer, manufacturer and distributor of diagnostic imaging agents, announced preliminary results from the first of two planned Phase 3 trials to assess the diagnostic efficacy of flurpiridaz F 18, an imaging agent used in positron emission tomography (PET) myocardial perfusion imaging (MPI) for the detection of coronary artery disease (CAD).

Subscribe Now